461 related articles for article (PubMed ID: 30791218)
1. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
Xie W; Xie L; Song X
Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.
Shen H; Che K; Cong L; Dong W; Zhang T; Liu Q; Du J
Oncotarget; 2017 May; 8(22):36812-36823. PubMed ID: 28415658
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis.
Ye P; Cai P; Xie J; Wei Y
PLoS One; 2021; 16(3):e0248775. PubMed ID: 33770081
[TBL] [Abstract][Full Text] [Related]
4. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Luo J; Shen L; Zheng D
Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
7. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.
Zhu Y; Yang T; Wu Q; Yang X; Hao J; Deng X; Yang S; Gu C; Wang Z
Cancer Med; 2020 Aug; 9(16):5699-5707. PubMed ID: 32628360
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.
Tang M; Deng Z; Li B; Peng Y; Song M; Liu J
Int J Biol Markers; 2017 Oct; 32(4):e421-e427. PubMed ID: 28885658
[TBL] [Abstract][Full Text] [Related]
12. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis.
Hao YX; Fu Q; Guo YY; Ye M; Zhao HX; Wang Q; Peng XM; Li QW; Wang RL; Xiao WH
Onco Targets Ther; 2017; 10():945-953. PubMed ID: 28243130
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
[TBL] [Abstract][Full Text] [Related]
16. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
Kuo YB; Chen JS; Fan CW; Li YS; Chan EC
Clin Chim Acta; 2014 Jun; 433():284-9. PubMed ID: 24685572
[TBL] [Abstract][Full Text] [Related]
17. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
[TBL] [Abstract][Full Text] [Related]
18. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
19. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]